Stablepharma named life sciences innovation awards winner
Bath, United Kingdom, December 4th, 2024 – Stablepharma Ltd today announces it was named a Fierce Life Sciences Innovation Awards winner by Fierce Biotech and Fierce Pharma in the Biotech Innovation category. The awards program highlights and showcases outstanding innovation that is driving improvements and transforming the industry.
“The Innovation Awards winners showcase the organizations that have demonstrated innovative solutions that have the greatest potential to save money, engage patients or revolutionize the healthcare industry,” says Rebecca Willumson, SVP and Publisher of Fierce Biotech and Fierce Pharma. “We are very pleased to congratulate the winners on their accomplishments.”
“We are immensely proud and grateful to have won the Biotech Innovation category with our entry of ‘Fridge-free Vaccine & Pharmaceutical Technology’, said Ozgur Tuncer, CEO & Executive Director, Stablepharma. “This is a groundbreaking achievement to be recognized as the category winner of this prestigious award and confirms the clear need to reduce the current level reliance on the global pharmaceutical cold chain”.
Stablepharma uses its proprietary StablevaX™ technology to reformulate and thermos-stabilise approved, existing and new vaccines in partnership with pharmaceutical manufacturers. StablevaX™ eliminates the need for refrigeration (ie; the cold chain) entirely for its fridge-free products, extending shelf-life and enabling strategic stockpiling at room temperature, no matter where in the world.
“Needless to say, we are extremely pleased to have won this prestigious Life Sciences Innovation Award, given the judging criteria and the quality of the applicants,” said Dr Steven Chatfield, Non-Executive Chairman, Stablepharma. He continued:
Stablepharma is rapidly progressing towards achieving our vision of make fridge-free vaccine and biological products a reality, which in effect means eliminating the requirement for temperature-controlled shipments of our lead candidate, SPVX02, a fridge-free vaccine for the prevention of Tetanus diphtheria.
An expert panel of judges reviewed the hundreds of awards submissions and determined which companies demonstrated innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.
Stablepharma is running a first-in-human clinical trial led by Professor Saul Faust OBE, at the NHS University Hospital of Southampton, and Dr Karen O’Hanlon, Chief Development Officer of Stablepharma, will start recruitment in February 2025 and is expected to be completed by the end of June 2025.
